+3.37% for Core Scientific stock — Uptrend builds despite mixed technical signals

Traders Union
All News
Financial News
Core Scientific up 3.37% at $17.05

Highlights

Jericho Capital Asset Management initiated a significant position in Core Scientific, acquiring nearly 11.7 million shares in Q3.
Core Scientific reported Q4 earnings per share of $0.42, beating analyst estimates, but revenue fell short of consensus at $79.76 million.
Technically, CORZ is showing buyer strength above key supports with 5-day trading expected between $15.80 and $17.30, but mixed momentum and overbought signals warn of caution near resistance.

Jericho Capital inflows and earnings surprise counter revenue miss

Jericho Capital Asset Management L.P. has acquired a new position in Core Scientific, purchasing 11,699,823 shares during the third quarter. The company most recently reported quarterly earnings on March 2, recording earnings per share of $0.42, ahead of analyst consensus estimates, and revenue of $79.76 million against a consensus forecast of $118.45 million.

Conflicted momentum builds caution near resistance as buyers dominate

At $17.05, CORZ is trading above the SMA-20 ($16.69) but just below the SMA-50 ($17.25), while remaining significantly above the SMA-200 ($15.95). This pattern suggests the short-term trend leans bullish, the medium-term faces resistance, and the long-term structure is supported by buyers; the Ichimoku Kijun level at $16.73 sits below price and acts as immediate support. Momentum signals are mixed: the daily MACD signals strong sell while ADX remains neutral, indicating a lack of clear trend strength. Oscillators are conflicted — RSI is neutral at 48.77, Stoch RSI is elevated at 71.89, and CCI is near zero, with BBP signaling overbought conditions and buyer dominance intraday. After opening at $17.03 (a small gap up from the previous close at $16.49), the price has held near the session high of $17.10, showing moderate volatility and persistent intraday strength, despite oscillators warning of a stretched market. These conflicting momentum and oscillator signals highlight growing caution as the price approaches key resistance.

High upside probability as volatility constrains short-term risk

For the next five sessions, the expected range is $15.80 to $17.30 — well within a ±10% band of current price, reflecting typical volatility for CORZ. Based on weekly indicators (RSI and MACD pointing to buy/strong buy, ADX neutral, MA-50 bullish), the probability of an upward move is very high (more than 80%), making downside less likely in this horizon. Baseline scenario: CORZ trades sideways between $15.80 and $17.30. In a bullish scenario, a sustained break above $17.30 opens the way for new highs. If selling pressure returns and price falls below $15.80, a move toward strong support in the $15.00s could follow.

Viktoras Karapetjanc, expert at Traders Union, notes that Core Scientific’s fundamentals have strengthened as institutional investors build positions and quarterly earnings drive optimism. He believes the technical structure is supportive, with price action holding above long-term averages and sentiment leaning constructive. Caution is warranted in the short term due to mixed momentum signals, but the macro backdrop and broad inflows suggest that downside risk is limited for now. "Core Scientific shows improving fundamentals and steady institutional interest, so I remain constructive while watching for a breakout above $17.30 in the coming days."

Earlier, analysts noted that Core Scientific was exhibiting mixed momentum as it straddled short-term gains and medium-term resistance, with institutional accumulation signaling a constructive shift. The latest trading action reinforces these themes, but with oscillators flashing overbought conditions and price nearing key resistance, traders should closely monitor for a potential breakout above $17.30 in the days ahead.

Source of Data: CORZ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.